Rintaro Hashizume

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Telomerase inhibitors for the treatment of brain tumors and the potential of intranasal delivery
    Rintaro Hashizume
    University of California San Francisco, Hellen Diller Family Cancer Research Center, Mission Bay, 1450 3rd Street, HD 200, San Francisco, CA 94158 0520, USA
    Curr Opin Mol Ther 12:168-75. 2010
  2. pmc New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163
    Rintaro Hashizume
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0520, USA
    Neuro Oncol 10:112-20. 2008
  3. pmc An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing
    Yasuyuki Aoki
    Department of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143 0112, USA
    J Neurooncol 108:29-35. 2012
  4. pmc A human brainstem glioma xenograft model enabled for bioluminescence imaging
    Rintaro Hashizume
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, 505 Parnassus Ave, Room M779, San Francisco, CA 94143 0112, USA
    J Neurooncol 96:151-9. 2010
  5. pmc Expression of miR-124 inhibits growth of medulloblastoma cells
    Joachim Silber
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143, USA
    Neuro Oncol 15:83-90. 2013
  6. doi request reprint Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment
    Rintaro Hashizume
    Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143 0520, USA
    J Neurooncol 110:305-13. 2012
  7. pmc Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy
    Emmanuelle Huillard
    Department of Pediatrics, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 109:8710-5. 2012
  8. pmc Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells
    Xiaodong Zhu
    Department of Anesthesia, University of California at San Francisco, San Francisco, California 94110, USA
    Mol Cancer Ther 9:2131-41. 2010
  9. pmc Targeting Wee1 for the treatment of pediatric high-grade gliomas
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, San Francisco, California S M, I K Department of Pediatrics, University of California, San Francisco, San Francisco, California S M, M D P, N G Brain Tumor Research Center, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California S M, R H, X Y, A K O, J P, M W T, C D J, M S B, N G, D A H K Department of Neurological Surgery, University of California, San Francisco, San Francisco, California S M, J P, I S, M D P, C D J, M S B, N G, D A H K Department of Radiation Oncology, University of California, San Francisco, San Francisco, California D A H K
    Neuro Oncol 16:352-60. 2014
  10. pmc Targeted therapy for BRAFV600E malignant astrocytoma
    Theodore P Nicolaides
    University of California, San Francisco, San Francisco, CA 94158, USA
    Clin Cancer Res 17:7595-604. 2011

Collaborators

Detail Information

Publications14

  1. ncbi request reprint Telomerase inhibitors for the treatment of brain tumors and the potential of intranasal delivery
    Rintaro Hashizume
    University of California San Francisco, Hellen Diller Family Cancer Research Center, Mission Bay, 1450 3rd Street, HD 200, San Francisco, CA 94158 0520, USA
    Curr Opin Mol Ther 12:168-75. 2010
    ..The IND of telomerase inhibitors represents a new therapeutic approach that appears to selectively kill tumor cells, without inducing toxic effects in the surrounding healthy brain tissue...
  2. pmc New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163
    Rintaro Hashizume
    Brain Tumor Research Center, Department of Neurological Surgery, University of California San Francisco, San Francisco, CA 94143 0520, USA
    Neuro Oncol 10:112-20. 2008
    ..These data support further development of intranasal delivery of tumor-specific therapeutic agents for brain tumor patients...
  3. pmc An experimental xenograft mouse model of diffuse pontine glioma designed for therapeutic testing
    Yasuyuki Aoki
    Department of Neurological Surgery and Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143 0112, USA
    J Neurooncol 108:29-35. 2012
    ..Our results demonstrate the feasibility of using an orthotopic brainstem tumor model in athymic mice, and for application to testing therapeutic agents in treating DIPG...
  4. pmc A human brainstem glioma xenograft model enabled for bioluminescence imaging
    Rintaro Hashizume
    Department of Neurological Surgery, Brain Tumor Research Center, University of California, 505 Parnassus Ave, Room M779, San Francisco, CA 94143 0112, USA
    J Neurooncol 96:151-9. 2010
    ..This model is well suited for pre-clinical testing of therapeutics that are being considered for treatment of patients with brainstem tumors...
  5. pmc Expression of miR-124 inhibits growth of medulloblastoma cells
    Joachim Silber
    Brain Tumor Research Center, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California 94143, USA
    Neuro Oncol 15:83-90. 2013
    ..Further testing of miR-124 will help define the ultimate therapeutic potential of preclinical models of medulloblastoma in conjunction with various delivery strategies for treatment...
  6. doi request reprint Characterization of a diffuse intrinsic pontine glioma cell line: implications for future investigations and treatment
    Rintaro Hashizume
    Department of Neurological Surgery, Brain Tumor Research Center, University of California San Francisco, San Francisco, CA 94143 0520, USA
    J Neurooncol 110:305-13. 2012
    ..The hTERT modified cells are tumorigenic in athymic rodents, and produce brainstem tumors that recapitulate the infiltrative growth of brainstem gliomas in patients...
  7. pmc Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy
    Emmanuelle Huillard
    Department of Pediatrics, University of California, San Francisco, CA 94143, USA
    Proc Natl Acad Sci U S A 109:8710-5. 2012
    ..Our findings indicate a rational therapeutic strategy for treating a subset of pediatric astrocytomas with BRAF(V600E) mutation and CDKN2A deficiency...
  8. pmc Identification of internalizing human single-chain antibodies targeting brain tumor sphere cells
    Xiaodong Zhu
    Department of Anesthesia, University of California at San Francisco, San Francisco, California 94110, USA
    Mol Cancer Ther 9:2131-41. 2010
    ....
  9. pmc Targeting Wee1 for the treatment of pediatric high-grade gliomas
    Sabine Mueller
    Department of Neurology, University of California, San Francisco, San Francisco, California S M, I K Department of Pediatrics, University of California, San Francisco, San Francisco, California S M, M D P, N G Brain Tumor Research Center, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California S M, R H, X Y, A K O, J P, M W T, C D J, M S B, N G, D A H K Department of Neurological Surgery, University of California, San Francisco, San Francisco, California S M, J P, I S, M D P, C D J, M S B, N G, D A H K Department of Radiation Oncology, University of California, San Francisco, San Francisco, California D A H K
    Neuro Oncol 16:352-60. 2014
    ..We investigated the efficacy of the Wee1 inhibitor MK-1775 in combination with radiation for the treatment of pediatric high-grade gliomas (HGGs), including diffuse intrinsic pontine gliomas (DIPGs)...
  10. pmc Targeted therapy for BRAFV600E malignant astrocytoma
    Theodore P Nicolaides
    University of California, San Francisco, San Francisco, CA 94158, USA
    Clin Cancer Res 17:7595-604. 2011
    ..We have investigated the incidence of BRAF(V600E) in additional pediatric patient cohorts and examined the effects of BRAF blockade in preclinical models of BRAF(V600E) and wild-type BRAF MA...
  11. ncbi request reprint Convection-enhanced delivery of targeted quantum dot-immunoliposome hybrid nanoparticles to intracranial brain tumor models
    Kevin C Weng
    UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA 94115, USA
    Nanomedicine (Lond) 8:1913-25. 2013
    ..The aim of this work is to evaluate combining targeting strategy and convection-enhanced delivery in brain tumor models by imaging quantum dot-immunoliposome hybrid nanoparticles...
  12. pmc The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression
    Kui Ming Chan
    Department of Biochemistry and Molecular Biology, University of California at San Francisco, San Francisco, California 94143, USA
    Genes Dev 27:985-90. 2013
    ..These results indicate that H3.3K27M mutation reprograms epigenetic landscape and gene expression, which may drive tumorigenesis...
  13. pmc Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing
    Rintaro Hashizume
    Brain Tumor Research Center, Department of Neurological Surgery, University ofCalifornia, San Diego, CA, USA
    Neuro Oncol 12:366-76. 2010
    ....
  14. pmc Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics
    Xi Huang
    Howard Hughes Medical Institute, San Francisco, CA 94158, USA
    Genes Dev 26:1780-96. 2012
    ....